{
    "info": {
        "nct_id": "NCT04577807",
        "official_title": "Lerapolturev (Formerly Known as PVSRIPO) With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma",
        "inclusion_criteria": "1. ≥ 18 years of age\n2. Prior CDC-recommended vaccination series against PV, and has received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to Day 1\n\n   a. NOTE: Patients who are unsure of their vaccination status must provide evidence of anti-PV immunity prior to enrollment, as applicable\n3. Has biopsy proven unresectable cutaneous melanoma and is willing to undergo tumor biopsy prior to the first dose of study drugs and at prespecified intervals during the study\n\n   1. Patients with ocular, acral or mucosal melanoma are not eligible\n   2. Patients with M1c or M1d disease are NOT eligble.\n   3. Submission of an archival biopsy sample is allowed in lieu of the baseline tumor biopsy, provided the tissue is ≤4 months old and the participant received no intervening systemic/intratumoral anti-cancer therapy since the biopsy was acquired.\n   4. Must have at least 1 lesion that is amenable to biopsy. The lesion must be safely accessible as determined by the investigator and should not be located at sites that require significant risk procedures to biopsy. Examples of sites considered to be of significant risk include but are not limited to the following: the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel wall.\n4. Has ≥ 2 melanoma lesions that are accurately measurable by caliper or a radiological method according to RECIST 1.1 criteria\n\n   1. One lesion must be injectable- defined as a visible or palpable cutaneous, subcutaneous, or nodal melanoma lesion ≥10 mm in longest diameter or multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥10 mm and where the minimum lesion size is ≥5 mm\n   2. Note that visceral lesions (eg, liver, lung, retroperitoneal, subpleural lesions) are not considered injectable for the purposes of this trial.\n5. Has had confirmed progression of disease (PD) while receiving at least 6 weeks (> 1 dose) of an FDA-approved anti-PD-1/L1 therapy (as monotherapy or in combination) for the treatment of melanoma. Note the following details:\n\n   1. Initial PD as defined by RECIST v1.1\n   2. Confirmation of PD per iRECIST must occur by repeat assessment ≥ 4 weeks from initial evidence of PD, in the absence of rapid clinical progression.\n   3. Those who discontinue anti-PD-1/L1 therapy after at least 6 weeks (> 1 dose) and have confirmed PD per iRECIST within 12 weeks of their last anti-PD-1/L1 dose are also eligible, provided the anti-PD-1/L1 was not stopped due to toxicity requiring permanent discontinuation\n   4. Those treated with anti-PD-1/L1 in the adjuvant setting and who have biopsy-confirmed progression either while receiving anti-PD-1/L1-based therapy or ≤ 12 weeks after their last dose of anti-PD-1/L1 therapy are allowed NOTE: Adjuvant is defined as therapy received after surgical resection of disease such that the patient has no evidence of disease when the anti-PD-1/L1 therapy is initiated. Patients with known BRAF mutation must have also failed or refused to receive BRAF-targeted therapy (alone or in combination with MEK inhibitor) to be eligible.\n6. Eastern Cooperative Oncology Group (ECOG) status of 0-1\n7. Serum lactate dehydrogenase (LDH) levels ≤ 3 x upper limit of normal (ULN)\n8. Adequate bone marrow, liver and renal function as assessed by the following:\n\n   1. Hemoglobin ≥ 9.0 g/dl, patients may be transfused\n   2. Lymphocyte count ≥ 0.5 x 10^9/L (500 µL)\n   3. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500 µL)\n   4. Platelet count ≥ 100 x 10^9/L (100,000 µL) without transfusion\n   5. AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions: Patients with documented liver metastases: AST and ALT ≤ 5 x ULN; Patients with documented liver or bone metastases: ALP ≤ 5 x ULN\n   6. Serum bilirubin ≤ 1.5 x ULN with the following exception: Patients with known Gilbert disease: serum bilirubin level ≤ 3 x ULN\n   7. Measured or calculated (per institutional standards) creatinine clearance ≥ 30 ml/min (GRF can also be used in place of creatinine clearance)\n   8. For patients not receiving therapeutic anticoagulation: INR, PT, PTT (or aPTT) ≤ 1.5 x ULN\n9. Life expectancy of >12 weeks\n10. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for the study, and is willing/able to participate in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Has biopsy-proven ocular, acral or mucosal melanoma\n2. Has M1c or M1d disease\n3. No more than one prior systemic anti-cancer regimen (monotherapy or combination) for management of melanoma. Additional details noted below:\n\n   1. Adjuvant anti-cancer therapy administered ≥ 6 months prior to the first injection of lerapolturev does NOT count as a line of treatment.\n   2. Patients with BRAF mutant melanoma may enroll if they have received ≤ 2 prior lines of systemic anti-cancer therapy only if one of those lines of therapy was a BRAF-targeted regimen (alone or in combination with MEK inhibitor).\n   3. A line of therapy is defined as a regimen in which at least 2 doses of systemic anti-cancer therapy (monotherapy or combination) was administered, and the regimen was discontinued because of progressive disease\n4. Uncontrolled tumor-related pain. Participants requiring pain medication must be on a stable regimen at study entry.\n\n   1. Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period\n   2. Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment\n5. Grade ≥2 pleural effusion, pericardial effusion, or ascites\n6. Active or history of autoimmune disease or immune deficiency within previous 2 years, with the following exceptions:\n\n   1. History of autoimmune-related endocrinopathy (e.g. adrenal insufficiency, hypothyroidism, Type 1 diabetes mellitus, etc.) that is managed by hormone replacement therapy (e.g. hydrocortisone, thyroid hormone, insulin, etc.)\n   2. Eczema, psoriasis, or lichen simplex chronicus with dermatologic manifestations only (eg, patients with psoriatic arthritis are excluded), provided all of the following conditions are met:\n\n   i. Rash must cover <10% of body surface area\n\n   ii. Disease is well-controlled at baseline and requires only low-potency topical corticosteroids\n\n   iii. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within 12 months of Day 1\n7. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n\n   a. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.\n8. History of a positive HIV RNA test (HIV 1 or 2 RNA by PCR)\n9. Known active hepatitis B virus (HBV) infection (chronic or acute)\n\n   a. NOTE: Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed.\n10. Known active hepatitis C virus (HCV) infection\n\n    a. NOTE: History of a positive HCV antibody test, but negative HCV RNA test is allowed.\n11. Active tuberculosis\n12. Significant cardiovascular disease, such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months of Day 1, unstable arrhythmia, or unstable angina\n13. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 elimination half-lives- whichever is shorter, prior to treatment, or has not recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy are eligible\n\n    1. Note: Anti-PD-1/L1 within 4 weeks prior to Day 1 is allowed\n    2. If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.\n14. History of other malignancy within 2 years prior to Day 1, with the exception of those with a negligible risk of metastasis or death (e.g., resected cutaneous basal cell carcinoma, or other cancers with 5-year OS of >90%)\n15. Severe infection within 4 weeks prior to Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n\n    a. Prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are allowed.\n16. Prior allogeneic stem cell or solid organ transplantation\n17. Treatment with a live, attenuated vaccine within 4 weeks prior to Day 1\n18. Treatment with systemic immunosuppressive medication within 4 weeks prior to Day 1, with the following exceptions:\n\n    1. Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible\n    2. Patients receiving mineralocorticoids (e.g., fludrocortisone), or systemic prednisone equivalent corticosteroid doses of <10mg per day are eligible for the study\n19. Known hypersensitivity to pembrolizumab, nivolumab, or any of the respective excipients\n20. Requires therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after each lerapolturev injection\n\n    a. NOTE: Participants receiving anticoagulation with warfarin at the time of study entry are allowed if they can be transitioned to an alternative anticoagulant (eg, low molecular weight heparin or direct oral anticoagulants) prior to the first dose of lerapolturev. Anyone transitioned from warfarin to an oral anticoagulant prior to the first dose of lerapolturev should have an INR <1.5x upper limit of normal in order to participate. Antiplatelet agents (eg, aspirin, clopidogrel, etc.) are not considered anticoagulants for the purposes of this study (ie, are allowed)\n21. A pregnant or nursing female, or women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception starting from signed ICF through 150 days after last anti-PD-1 dose\n22. History of human serum albumin allergy\n23. History of neurological complications due to polio virus infection\n24. History of agammaglobulinemia\n25. Concurrent participation in a separate interventional clinical trial during this study.\n26. Any underlying medical condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromises the participant's well-being) or that could prevent, limit, or confound protocol-specified assessments",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Prior CDC-recommended vaccination series against PV, and has received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to Day 1",
            "criterions": [
                {
                    "exact_snippets": "Prior CDC-recommended vaccination series against PV",
                    "criterion": "CDC-recommended vaccination series against PV",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "has received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to Day 1",
                    "criterion": "boost immunization with trivalent IPOL®",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 6,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with M1c or M1d disease are NOT eligble.",
            "criterions": [
                {
                    "exact_snippets": "Patients with M1c or M1d disease are NOT eligble.",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "M1c",
                                "M1d"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Lymphocyte count ≥ 0.5 x 10^9/L (500 µL)",
            "criterions": [
                {
                    "exact_snippets": "Lymphocyte count ≥ 0.5 x 10^9/L (500 µL)",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. NOTE: Patients who are unsure of their vaccination status must provide evidence of anti-PV immunity prior to enrollment, as applicable",
            "criterions": [
                {
                    "exact_snippets": "Patients who are unsure of their vaccination status must provide evidence of anti-PV immunity prior to enrollment",
                    "criterion": "anti-PV immunity",
                    "requirements": [
                        {
                            "requirement_type": "evidence of immunity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Note that visceral lesions (eg, liver, lung, retroperitoneal, subpleural lesions) are not considered injectable for the purposes of this trial.",
            "criterions": [
                {
                    "exact_snippets": "visceral lesions (eg, liver, lung, retroperitoneal, subpleural lesions) are not considered injectable",
                    "criterion": "visceral lesions",
                    "requirements": [
                        {
                            "requirement_type": "injectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eastern Cooperative Oncology Group (ECOG) status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Platelet count ≥ 100 x 10^9/L (100,000 µL) without transfusion",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100 x 10^9/L (100,000 µL) without transfusion",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "transfusion support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500 µL)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500 µL)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Hemoglobin ≥ 9.0 g/dl, patients may be transfused",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9.0 g/dl",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Confirmation of PD per iRECIST must occur by repeat assessment ≥ 4 weeks from initial evidence of PD, in the absence of rapid clinical progression.",
            "criterions": [
                {
                    "exact_snippets": "Confirmation of PD per iRECIST must occur by repeat assessment ≥ 4 weeks from initial evidence of PD",
                    "criterion": "progressive disease (PD) confirmation per iRECIST",
                    "requirements": [
                        {
                            "requirement_type": "confirmation timing",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of rapid clinical progression",
                    "criterion": "rapid clinical progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Serum lactate dehydrogenase (LDH) levels ≤ 3 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum lactate dehydrogenase (LDH) levels ≤ 3 x upper limit of normal (ULN)",
                    "criterion": "serum lactate dehydrogenase (LDH) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate bone marrow, liver and renal function as assessed by the following:",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow ... function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... liver ... function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Has ≥ 2 melanoma lesions that are accurately measurable by caliper or a radiological method according to RECIST 1.1 criteria",
            "criterions": [
                {
                    "exact_snippets": "Has ≥ 2 melanoma lesions",
                    "criterion": "number of melanoma lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable by caliper or a radiological method according to RECIST 1.1 criteria",
                    "criterion": "measurability of melanoma lesions",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurement method",
                            "expected_value": [
                                "caliper",
                                "radiological method"
                            ]
                        },
                        {
                            "requirement_type": "measurement standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Measured or calculated (per institutional standards) creatinine clearance ≥ 30 ml/min (GRF can also be used in place of creatinine clearance)",
            "criterions": [
                {
                    "exact_snippets": "Measured or calculated (per institutional standards) creatinine clearance ≥ 30 ml/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "GRF can also be used in place of creatinine clearance",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Life expectancy of >12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of >12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Submission of an archival biopsy sample is allowed in lieu of the baseline tumor biopsy, provided the tissue is ≤4 months old and the participant received no intervening systemic/intratumoral anti-cancer therapy since the biopsy was acquired.",
            "criterions": [
                {
                    "exact_snippets": "Submission of an archival biopsy sample is allowed in lieu of the baseline tumor biopsy",
                    "criterion": "archival biopsy sample submission",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue is ≤4 months old",
                    "criterion": "archival biopsy tissue age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participant received no intervening systemic/intratumoral anti-cancer therapy since the biopsy was acquired",
                    "criterion": "intervening systemic/intratumoral anti-cancer therapy since biopsy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for the study, and is willing/able to participate in the study",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent form (ICF)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "indicating that participant understands the purpose of, and procedures required for the study",
                    "criterion": "study purpose and procedures comprehension",
                    "requirements": [
                        {
                            "requirement_type": "comprehension",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is willing/able to participate in the study",
                    "criterion": "willingness and ability to participate",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Must have at least 1 lesion that is amenable to biopsy. The lesion must be safely accessible as determined by the investigator and should not be located at sites that require significant risk procedures to biopsy. Examples of sites considered to be of significant risk include but are not limited to the following: the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel wall.",
            "criterions": [
                {
                    "exact_snippets": "Must have at least 1 lesion",
                    "criterion": "number of lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lesion that is amenable to biopsy",
                    "criterion": "lesion amenability to biopsy",
                    "requirements": [
                        {
                            "requirement_type": "amenability to biopsy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "The lesion must be safely accessible as determined by the investigator",
                    "criterion": "lesion accessibility for biopsy",
                    "requirements": [
                        {
                            "requirement_type": "safe accessibility for biopsy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should not be located at sites that require significant risk procedures to biopsy. Examples of sites considered to be of significant risk include but are not limited to the following: the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel wall.",
                    "criterion": "lesion location",
                    "requirements": [
                        {
                            "requirement_type": "location exclusion",
                            "expected_value": [
                                "brain",
                                "lung",
                                "mediastinum",
                                "pancreas",
                                "endoscopic procedures extending beyond the esophagus, stomach, or bowel wall"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Has had confirmed progression of disease (PD) while receiving at least 6 weeks (> 1 dose) of an FDA-approved anti-PD-1/L1 therapy (as monotherapy or in combination) for the treatment of melanoma. Note the following details:",
            "criterions": [
                {
                    "exact_snippets": "Has had confirmed progression of disease (PD)",
                    "criterion": "progression of disease",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "while receiving at least 6 weeks (> 1 dose) of an FDA-approved anti-PD-1/L1 therapy (as monotherapy or in combination) for the treatment of melanoma",
                    "criterion": "anti-PD-1/L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "dose_count",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "dose"
                            }
                        },
                        {
                            "requirement_type": "FDA-approval_status",
                            "expected_value": "approved"
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "monotherapy",
                                "combination"
                            ]
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "melanoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Has biopsy proven unresectable cutaneous melanoma and is willing to undergo tumor biopsy prior to the first dose of study drugs and at prespecified intervals during the study",
            "criterions": [
                {
                    "exact_snippets": "biopsy proven unresectable cutaneous melanoma",
                    "criterion": "cutaneous melanoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "biopsy confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to undergo tumor biopsy prior to the first dose of study drugs",
                    "criterion": "willingness to undergo tumor biopsy prior to first dose",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to first dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to undergo tumor biopsy ... at prespecified intervals during the study",
                    "criterion": "willingness to undergo tumor biopsy at prespecified intervals",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at prespecified intervals during the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Those treated with anti-PD-1/L1 in the adjuvant setting and who have biopsy-confirmed progression either while receiving anti-PD-1/L1-based therapy or ≤ 12 weeks after their last dose of anti-PD-1/L1 therapy are allowed NOTE: Adjuvant is defined as therapy received after surgical resection of disease such that the patient has no evidence of disease when the anti-PD-1/L1 therapy is initiated. Patients with known BRAF mutation must have also failed or refused to receive BRAF-targeted therapy (alone or in combination with MEK inhibitor) to be eligible.",
            "criterions": [
                {
                    "exact_snippets": "treated with anti-PD-1/L1 in the adjuvant setting",
                    "criterion": "anti-PD-1/L1 therapy in adjuvant setting",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy-confirmed progression either while receiving anti-PD-1/L1-based therapy or ≤ 12 weeks after their last dose of anti-PD-1/L1 therapy",
                    "criterion": "progression after anti-PD-1/L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression confirmation",
                            "expected_value": "biopsy-confirmed"
                        },
                        {
                            "requirement_type": "progression timing",
                            "expected_value": [
                                "while receiving anti-PD-1/L1-based therapy",
                                "≤ 12 weeks after last dose of anti-PD-1/L1 therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with known BRAF mutation must have also failed or refused to receive BRAF-targeted therapy (alone or in combination with MEK inhibitor)",
                    "criterion": "BRAF-targeted therapy in BRAF-mutant patients",
                    "requirements": [
                        {
                            "requirement_type": "BRAF mutation status",
                            "expected_value": "known mutation"
                        },
                        {
                            "requirement_type": "BRAF-targeted therapy history",
                            "expected_value": [
                                "failed",
                                "refused"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Initial PD as defined by RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Initial PD as defined by RECIST v1.1",
                    "criterion": "progressive disease (PD)",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "initial"
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. For patients not receiving therapeutic anticoagulation: INR, PT, PTT (or aPTT) ≤ 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "patients not receiving therapeutic anticoagulation",
                    "criterion": "therapeutic anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "INR ... ≤ 1.5 x ULN",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PT ... ≤ 1.5 x ULN",
                    "criterion": "PT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PTT (or aPTT) ≤ 1.5 x ULN",
                    "criterion": "PTT or aPTT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Those who discontinue anti-PD-1/L1 therapy after at least 6 weeks (> 1 dose) and have confirmed PD per iRECIST within 12 weeks of their last anti-PD-1/L1 dose are also eligible, provided the anti-PD-1/L1 was not stopped due to toxicity requiring permanent discontinuation",
            "criterions": [
                {
                    "exact_snippets": "discontinue anti-PD-1/L1 therapy after at least 6 weeks (> 1 dose)",
                    "criterion": "anti-PD-1/L1 therapy discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "duration of therapy before discontinuation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "number of doses before discontinuation",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed PD per iRECIST within 12 weeks of their last anti-PD-1/L1 dose",
                    "criterion": "progressive disease (PD) per iRECIST",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time from last anti-PD-1/L1 dose to PD confirmation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anti-PD-1/L1 was not stopped due to toxicity requiring permanent discontinuation",
                    "criterion": "reason for anti-PD-1/L1 discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "toxicity requiring permanent discontinuation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Serum bilirubin ≤ 1.5 x ULN with the following exception: Patients with known Gilbert disease: serum bilirubin level ≤ 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin ≤ 1.5 x ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with known Gilbert disease: serum bilirubin level ≤ 3 x ULN",
                    "criterion": "serum bilirubin (in patients with known Gilbert disease)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. One lesion must be injectable- defined as a visible or palpable cutaneous, subcutaneous, or nodal melanoma lesion ≥10 mm in longest diameter or multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥10 mm and where the minimum lesion size is ≥5 mm",
            "criterions": [
                {
                    "exact_snippets": "One lesion must be injectable- defined as a visible or palpable cutaneous, subcutaneous, or nodal melanoma lesion ≥10 mm in longest diameter",
                    "criterion": "melanoma lesion",
                    "requirements": [
                        {
                            "requirement_type": "injectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "visibility or palpability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "cutaneous",
                                "subcutaneous",
                                "nodal"
                            ]
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "count",
                            "expected_value": ">=1"
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥10 mm and where the minimum lesion size is ≥5 mm",
                    "criterion": "melanoma lesions (multiple)",
                    "requirements": [
                        {
                            "requirement_type": "injectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "count",
                            "expected_value": ">1"
                        },
                        {
                            "requirement_type": "aggregate size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "minimum individual lesion size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "mm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients with ocular, acral or mucosal melanoma are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients with ocular, acral or mucosal melanoma are not eligible",
                    "criterion": "ocular melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with ocular, acral or mucosal melanoma are not eligible",
                    "criterion": "acral melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with ocular, acral or mucosal melanoma are not eligible",
                    "criterion": "mucosal melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. ≥ 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions: Patients with documented liver metastases: AST and ALT ≤ 5 x ULN; Patients with documented liver or bone metastases: ALP ≤ 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN)",
                    "criterion": "AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN)",
                    "criterion": "ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN)",
                    "criterion": "alkaline phosphatase (ALP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with documented liver metastases: AST and ALT ≤ 5 x ULN",
                    "criterion": "AST",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "documented liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with documented liver metastases: AST and ALT ≤ 5 x ULN",
                    "criterion": "ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "documented liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with documented liver or bone metastases: ALP ≤ 5 x ULN",
                    "criterion": "alkaline phosphatase (ALP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": [
                                "documented liver metastases",
                                "documented bone metastases"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "10. Known active hepatitis C virus (HCV) infection",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis C virus (HCV) infection",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. A pregnant or nursing female, or women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception starting from signed ICF through 150 days after last anti-PD-1 dose",
            "criterions": [
                {
                    "exact_snippets": "A pregnant ... female",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing female",
                    "criterion": "nursing (breastfeeding)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of child-bearing potential ... not willing/able to use medically acceptable forms of contraception starting from signed ICF through 150 days after last anti-PD-1 dose",
                    "criterion": "contraception use in women of child-bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": "from signed ICF through 150 days after last anti-PD-1 dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "men who are sexually active and not willing/able to use medically acceptable forms of contraception starting from signed ICF through 150 days after last anti-PD-1 dose",
                    "criterion": "contraception use in sexually active men",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": "from signed ICF through 150 days after last anti-PD-1 dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Treatment with a live, attenuated vaccine within 4 weeks prior to Day 1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with a live, attenuated vaccine within 4 weeks prior to Day 1",
                    "criterion": "treatment with a live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Requires therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after each lerapolturev injection",
            "criterions": [
                {
                    "exact_snippets": "Requires therapeutic anticoagulation",
                    "criterion": "therapeutic anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cannot discontinue anticoagulation safely during the day prior, day of, and day after each lerapolturev injection",
                    "criterion": "ability to discontinue anticoagulation safely",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": [
                                "day prior to injection",
                                "day of injection",
                                "day after injection"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii. Disease is well-controlled at baseline and requires only low-potency topical corticosteroids",
            "criterions": [
                {
                    "exact_snippets": "Disease is well-controlled at baseline",
                    "criterion": "disease control status at baseline",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well-controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requires only low-potency topical corticosteroids",
                    "criterion": "corticosteroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "potency",
                            "expected_value": "low-potency"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "topical"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Grade ≥2 pleural effusion, pericardial effusion, or ascites",
            "criterions": [
                {
                    "exact_snippets": "Grade ≥2 pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥2 ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥2 ... ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. NOTE: History of a positive HCV antibody test, but negative HCV RNA test is allowed.",
            "criterions": [
                {
                    "exact_snippets": "History of a positive HCV antibody test, but negative HCV RNA test is allowed.",
                    "criterion": "HCV infection status",
                    "requirements": [
                        {
                            "requirement_type": "antibody test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "RNA test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. History of autoimmune-related endocrinopathy (e.g. adrenal insufficiency, hypothyroidism, Type 1 diabetes mellitus, etc.) that is managed by hormone replacement therapy (e.g. hydrocortisone, thyroid hormone, insulin, etc.)",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune-related endocrinopathy (e.g. adrenal insufficiency, hypothyroidism, Type 1 diabetes mellitus, etc.)",
                    "criterion": "autoimmune-related endocrinopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "managed by hormone replacement therapy (e.g. hydrocortisone, thyroid hormone, insulin, etc.)",
                    "criterion": "hormone replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. NOTE: Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed.",
                    "criterion": "HBsAg test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed.",
                    "criterion": "total hepatitis B core antibody (HBcAb) test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. History of agammaglobulinemia",
            "criterions": [
                {
                    "exact_snippets": "History of agammaglobulinemia",
                    "criterion": "agammaglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. History of neurological complications due to polio virus infection",
            "criterions": [
                {
                    "exact_snippets": "History of neurological complications due to polio virus infection",
                    "criterion": "neurological complications due to polio virus infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Known active hepatitis B virus (HBV) infection (chronic or acute)",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis B virus (HBV) infection (chronic or acute)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": [
                                "chronic",
                                "acute"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Adjuvant anti-cancer therapy administered ≥ 6 months prior to the first injection of lerapolturev does NOT count as a line of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Adjuvant anti-cancer therapy administered ≥ 6 months prior to the first injection of lerapolturev",
                    "criterion": "adjuvant anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_time_before_first_lerapolturev_injection",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should treated prior to enrollment.",
                    "criterion": "symptomatic lesions amenable to palliative radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients should be recovered from the effects of radiation.",
                    "criterion": "recovery from effects of radiation",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "There is no required minimum recovery period",
                    "criterion": "recovery period after radiation",
                    "requirements": [
                        {
                            "requirement_type": "minimum recovery period",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Treatment with systemic immunosuppressive medication within 4 weeks prior to Day 1, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medication within 4 weeks prior to Day 1",
                    "criterion": "systemic immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. A line of therapy is defined as a regimen in which at least 2 doses of systemic anti-cancer therapy (monotherapy or combination) was administered, and the regimen was discontinued because of progressive disease",
            "criterions": [
                {
                    "exact_snippets": "at least 2 doses of systemic anti-cancer therapy (monotherapy or combination) was administered",
                    "criterion": "systemic anti-cancer therapy doses",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the regimen was discontinued because of progressive disease",
                    "criterion": "regimen discontinuation reason",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_reason",
                            "expected_value": "progressive disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. Rash must cover <10% of body surface area",
            "criterions": [
                {
                    "exact_snippets": "Rash must cover <10% of body surface area",
                    "criterion": "rash body surface area coverage",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "% of body surface area"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Prior allogeneic stem cell or solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell or solid organ transplantation",
                    "criterion": "history of transplantation",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "allogeneic stem cell",
                                "solid organ"
                            ]
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": "prior"
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Any underlying medical condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromises the participant's well-being) or that could prevent, limit, or confound protocol-specified assessments",
            "criterions": [
                {
                    "exact_snippets": "Any underlying medical condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromises the participant's well-being)",
                    "criterion": "underlying medical condition",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of best interest",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any underlying medical condition ... that could prevent, limit, or confound protocol-specified assessments",
                    "criterion": "underlying medical condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to prevent, limit, or confound protocol-specified assessments",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. Concurrent participation in a separate interventional clinical trial during this study.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent participation in a separate interventional clinical trial during this study.",
                    "criterion": "participation in a separate interventional clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "concurrent participation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "potential for functional deficit or intractable pain with further growth",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "epidural metastasis that is not currently associated with spinal cord compression",
                    "criterion": "epidural metastasis",
                    "requirements": [
                        {
                            "requirement_type": "spinal cord compression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Eczema, psoriasis, or lichen simplex chronicus with dermatologic manifestations only (eg, patients with psoriatic arthritis are excluded), provided all of the following conditions are met:",
            "criterions": [
                {
                    "exact_snippets": "Eczema, psoriasis, or lichen simplex chronicus with dermatologic manifestations only (eg, patients with psoriatic arthritis are excluded)",
                    "criterion": "eczema, psoriasis, or lichen simplex chronicus",
                    "requirements": [
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        },
                        {
                            "requirement_type": "comorbidity exclusion",
                            "expected_value": "psoriatic arthritis excluded"
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. Prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Prophylactic antibiotics ... are allowed",
                    "criterion": "prophylactic antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. No more than one prior systemic anti-cancer regimen (monotherapy or combination) for management of melanoma. Additional details noted below:",
            "criterions": [
                {
                    "exact_snippets": "No more than one prior systemic anti-cancer regimen (monotherapy or combination) for management of melanoma",
                    "criterion": "prior systemic anti-cancer regimens for melanoma",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. NOTE: Participants receiving anticoagulation with warfarin at the time of study entry are allowed if they can be transitioned to an alternative anticoagulant (eg, low molecular weight heparin or direct oral anticoagulants) prior to the first dose of lerapolturev. Anyone transitioned from warfarin to an oral anticoagulant prior to the first dose of lerapolturev should have an INR <1.5x upper limit of normal in order to participate. Antiplatelet agents (eg, aspirin, clopidogrel, etc.) are not considered anticoagulants for the purposes of this study (ie, are allowed)",
            "criterions": [
                {
                    "exact_snippets": "Participants receiving anticoagulation with warfarin at the time of study entry are allowed if they can be transitioned to an alternative anticoagulant (eg, low molecular weight heparin or direct oral anticoagulants) prior to the first dose of lerapolturev.",
                    "criterion": "anticoagulation with warfarin",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "transition to alternative anticoagulant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Anyone transitioned from warfarin to an oral anticoagulant prior to the first dose of lerapolturev should have an INR <1.5x upper limit of normal in order to participate.",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Antiplatelet agents (eg, aspirin, clopidogrel, etc.) are not considered anticoagulants for the purposes of this study (ie, are allowed)",
                    "criterion": "antiplatelet agent use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. History of other malignancy within 2 years prior to Day 1, with the exception of those with a negligible risk of metastasis or death (e.g., resected cutaneous basal cell carcinoma, or other cancers with 5-year OS of >90%)",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancy within 2 years prior to Day 1",
                    "criterion": "history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Has M1c or M1d disease",
            "criterions": [
                {
                    "exact_snippets": "Has M1c or M1d disease",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "M1c",
                                "M1d"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Uncontrolled tumor-related pain. Participants requiring pain medication must be on a stable regimen at study entry.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled tumor-related pain",
                    "criterion": "tumor-related pain",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants requiring pain medication must be on a stable regimen at study entry",
                    "criterion": "pain medication regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Severe infection within 4 weeks prior to Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia",
            "criterions": [
                {
                    "exact_snippets": "Severe infection within 4 weeks prior to Day 1",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "time since occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. History of human serum albumin allergy",
            "criterions": [
                {
                    "exact_snippets": "History of human serum albumin allergy",
                    "criterion": "human serum albumin allergy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.",
            "criterions": [
                {
                    "exact_snippets": "received major surgery",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment",
                    "criterion": "recovery from surgery toxicity/complications",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Active or history of autoimmune disease or immune deficiency within previous 2 years, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Active or history of autoimmune disease or immune deficiency within previous 2 years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Active or history of autoimmune disease or immune deficiency within previous 2 years",
                    "criterion": "immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients receiving mineralocorticoids (e.g., fludrocortisone), or systemic prednisone equivalent corticosteroid doses of <10mg per day are eligible for the study",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving mineralocorticoids (e.g., fludrocortisone) ... are eligible for the study",
                    "criterion": "mineralocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic prednisone equivalent corticosteroid doses of <10mg per day are eligible for the study",
                    "criterion": "systemic prednisone equivalent corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg per day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible",
            "criterions": [
                {
                    "exact_snippets": "Participants who received acute, low-dose systemic immunosuppressant medication ... are eligible",
                    "criterion": "systemic immunosuppressant medication (acute, low-dose)",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "acute, low-dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants who received ... a one-time pulse dose of systemic immunosuppressant medication ... are eligible",
                    "criterion": "systemic immunosuppressant medication (one-time pulse dose)",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "one-time pulse dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Note: Anti-PD-1/L1 within 4 weeks prior to Day 1 is allowed",
            "criterions": [
                {
                    "exact_snippets": "Anti-PD-1/L1 within 4 weeks prior to Day 1 is allowed",
                    "criterion": "Anti-PD-1/L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "administration timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to Day 1"
                            }
                        },
                        {
                            "requirement_type": "permissibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bronchiolitis obliterans",
                    "criterion": "bronchiolitis obliterans",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced or idiopathic pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "drug-induced",
                                "idiopathic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_CT_scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Significant cardiovascular disease, such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months of Day 1, unstable arrhythmia, or unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class II or greater cardiac disease",
                    "criterion": "cardiac disease (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction, or cerebrovascular accident within 3 months of Day 1",
                    "criterion": "myocardial infarction or cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with BRAF mutant melanoma may enroll if they have received ≤ 2 prior lines of systemic anti-cancer therapy only if one of those lines of therapy was a BRAF-targeted regimen (alone or in combination with MEK inhibitor).",
            "criterions": [
                {
                    "exact_snippets": "Patients with BRAF mutant melanoma",
                    "criterion": "BRAF mutant melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received ≤ 2 prior lines of systemic anti-cancer therapy",
                    "criterion": "prior lines of systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "only if one of those lines of therapy was a BRAF-targeted regimen (alone or in combination with MEK inhibitor)",
                    "criterion": "BRAF-targeted regimen in prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence_in_prior_therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 elimination half-lives- whichever is shorter, prior to treatment, or has not recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy are eligible",
            "criterions": [
                {
                    "exact_snippets": "Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 elimination half-lives- whichever is shorter, prior to treatment",
                    "criterion": "prior systemic anti-cancer therapy (including investigational agents)",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "elimination half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not recovered from all AEs due to previous therapies to ≤Grade 1 or baseline",
                    "criterion": "recovery from adverse events due to previous therapies",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "recovery to baseline",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ≤Grade 2 neuropathy are eligible",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Has biopsy-proven ocular, acral or mucosal melanoma",
            "criterions": [
                {
                    "exact_snippets": "biopsy-proven ocular ... melanoma",
                    "criterion": "ocular melanoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy-proven ... acral ... melanoma",
                    "criterion": "acral melanoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy-proven ... mucosal melanoma",
                    "criterion": "mucosal melanoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within 12 months of Day 1",
            "criterions": [
                {
                    "exact_snippets": "No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within 12 months of Day 1",
                    "criterion": "acute exacerbations of the underlying condition requiring specified therapies",
                    "requirements": [
                        {
                            "requirement_type": "occurrence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Known hypersensitivity to pembrolizumab, nivolumab, or any of the respective excipients",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to pembrolizumab",
                    "criterion": "hypersensitivity to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... nivolumab",
                    "criterion": "hypersensitivity to nivolumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... any of the respective excipients",
                    "criterion": "hypersensitivity to excipients of pembrolizumab or nivolumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.",
            "criterions": [
                {
                    "exact_snippets": "History of radiation pneumonitis in the radiation field (fibrosis) is allowed.",
                    "criterion": "history of radiation pneumonitis in the radiation field (fibrosis)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of a positive HIV RNA test (HIV 1 or 2 RNA by PCR)",
            "criterions": [
                {
                    "exact_snippets": "History of a positive HIV RNA test (HIV 1 or 2 RNA by PCR)",
                    "criterion": "HIV RNA test result",
                    "requirements": [
                        {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "HIV 1 RNA by PCR",
                                "HIV 2 RNA by PCR"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}